Glenmark Pharma launches nasal spray Ryaltris in India

Glenmark Pharma launches nasal spray Ryaltris in India
PTI
Share
Font Size
Save
Comment
Synopsis

Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India.

Agencies
on Monday announced of launch its nasal spray Ryaltris, used for treatment of moderate to severe allergic rhinitis, in India.

Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost effective treatment option in the country, Glenmark said in a regulatory filing.

"While the average cost of therapy of top 10 existing brands of the similar drug category is Rs 365, Glenmark's Ryaltris -AZ nasal spray has been launched at a breakthrough price of Rs 175 per pack of 75 metered doses (MD)," the company added.

Alok Malik, Group Vice President and Business Head, India Formulations said: "Respiratory segment is a key area of focus for Glenmark and the launch of this product will enable us to improve access to allergic rhinitis treatment by providing an effective, convenient, world-class and affordable treatment option to patients in India".

Shares of Glenmark Pharma were trading 0.14 per cent higher at Rs 577.45 apiece on BSE.

Read More News on

(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

ETPrime stories of the day

Read before you invest. Insights on Glenmark Pharmaceuticals Ltd.. Explore Now